AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A method for treating obesity in a mammalian subject, which comprises administration of an effective amount of a prostaglandin compound to the subject.

2. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is the compound as shown by the following general formula (I)[[.]]:



(I)

wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower) alkyl, lower alkanoyloxy or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is $-CH_3$, or $-CH_2OH$, $-COCH_2OH$, -COOH or a functional derivative thereof;

B is single bond, $-CH_2-CH_2-$, -CH=CH-, $-C\equiv C-$, $-CH_2-CH_2-CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-C\equiv C-CH_2-$ or $-CH_2-C\equiv C-$;

Z is



wherein R_4 and R_5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R_4 and R_5 are not hydroxy and lower alkoxy at the same time;

R_1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one ~~of~~ carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and

Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; or heterocyclic-oxy.

3. (original): The method as described in Claim 1, wherein said prostaglandin compound is 16-mono or dihalogen-prostaglandin compound.

4. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-16-mono or dihalogen-prostaglandin compound.

5. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-l6-mono or dihalogen-prostaglandin compound.

6. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-16-mono or difluoro-prostaglandin compound.

7. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-l5-keto-16-mono or difluoro-prostaglandin compound.

8. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-l6-mono or dihalogen-prostaglandin E compound.

9. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-l5-keto-16-mono or dihalogen-prostaglandin E compound.

10. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-16,16-difluoro-prostaglandin E_1 compound.

11. (original): The method as described in Claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E_1 compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E_1 compound.

12. (original): The method as described in Claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μg/kg per day.

13. (original): The method as described in Claim 12, wherein the administration is at the amount of 0.1-10 μg/kg per day.

14. (canceled).

15. (canceled).